<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35277883</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1651-2227</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>111</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Acta paediatrica (Oslo, Norway : 1992)</Title>
          <ISOAbbreviation>Acta Paediatr</ISOAbbreviation>
        </Journal>
        <ArticleTitle>We need pertussis vaccine that protects children for longer without the adverse effects of whole-cell versions.</ArticleTitle>
        <Pagination>
          <StartPage>912</StartPage>
          <EndPage>913</EndPage>
          <MedlinePgn>912-913</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/apa.16311</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nilsson</LastName>
            <ForeName>Lennart Jan</ForeName>
            <Initials>LJ</Initials>
            <Identifier Source="ORCID">0000-0002-5680-6367</Identifier>
            <AffiliationInfo>
              <Affiliation>Allergy Center, Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016421">Editorial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Norway</Country>
        <MedlineTA>Acta Paediatr</MedlineTA>
        <NlmUniqueID>9205968</NlmUniqueID>
        <ISSNLinking>0803-5253</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010567">Pertussis Vaccine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001886" MajorTopicYN="N">Bordetella pertussis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010567" MajorTopicYN="Y">Pertussis Vaccine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014917" MajorTopicYN="Y">Whooping Cough</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35277883</ArticleId>
        <ArticleId IdType="doi">10.1111/apa.16311</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Aronsson B, Apelqvist E, Jämtberg K, Källberg H, Olin P, Storsaeter J. Long-term follow up of the effectiveness of one whole cell and two acellular pertussis vaccines based on a randomised controlled vaccine trial in Sweden. Acta Paediatr. 2021. doi:10.1111/apa.16184</Citation>
        </Reference>
        <Reference>
          <Citation>Vickers D, Ross AG, Mainar-Jaime RC, Neudorf C, Shah S. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children. CMAJ. 2006;175:1213-1217.</Citation>
        </Reference>
        <Reference>
          <Citation>Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013;131:e1716-e1722.</Citation>
        </Reference>
        <Reference>
          <Citation>McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics. 2015;135:331-343.</Citation>
        </Reference>
        <Reference>
          <Citation>Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5 and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics. 2006;118:978-984.</Citation>
        </Reference>
        <Reference>
          <Citation>Carlsson RM, von Segebaden K, Bergström J, Kling AM, Nilsson L. Surveillance of infant pertussis in Sweden 1998-2012; severity of disease in relation to the national vaccination programme. Eurosurveillance. 2015;20(6):21032.</Citation>
        </Reference>
        <Reference>
          <Citation>Vizzotti C, Neyro S, Katz N, et al. Maternal immunization in Argentina: a storyline from the prospective of a middle income country. Vaccine. 2015;33:6413-6419.</Citation>
        </Reference>
        <Reference>
          <Citation>Bolotin S, Harvill ET, Crowcroft NS. What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine. FEMS Pathog Dis. 2015;73:ftv057.</Citation>
        </Reference>
        <Reference>
          <Citation>Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA. 2012;308:454-456.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
